Prestige Consumer Healthcare Inc (PBH) Receives Average Rating of “Hold” from Analysts

Prestige Consumer Healthcare Inc (NYSE:PBH) has been assigned an average recommendation of “Hold” from the six brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $38.50.

Several equities research analysts have issued reports on PBH shares. Zacks Investment Research upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a report on Wednesday, January 2nd. DA Davidson upped their price objective on Prestige Consumer Healthcare to $38.00 and gave the stock a “neutral” rating in a research note on Monday, November 5th. Finally, ValuEngine lowered Prestige Consumer Healthcare from a “hold” rating to a “sell” rating in a research report on Friday, November 16th.

Prestige Consumer Healthcare stock opened at $31.38 on Friday. The stock has a market cap of $1.60 billion, a P/E ratio of 12.16, a P/E/G ratio of 1.53 and a beta of 1.19. Prestige Consumer Healthcare has a 52 week low of $27.84 and a 52 week high of $46.44. The company has a debt-to-equity ratio of 1.59, a current ratio of 2.15 and a quick ratio of 1.38.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.63 by $0.02. The company had revenue of $239.36 million during the quarter, compared to analysts’ expectations of $236.28 million. Prestige Consumer Healthcare had a return on equity of 11.82% and a net margin of 33.38%. The firm’s revenue was down 7.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.61 EPS. As a group, sell-side analysts forecast that Prestige Consumer Healthcare will post 2.88 earnings per share for the current year.

In related news, EVP Timothy Connors sold 74,707 shares of the stock in a transaction that occurred on Wednesday, November 14th. The stock was sold at an average price of $38.96, for a total transaction of $2,910,584.72. Following the completion of the sale, the executive vice president now owns 95,382 shares in the company, valued at approximately $3,716,082.72. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.14% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC increased its stake in shares of Prestige Consumer Healthcare by 6.9% in the 3rd quarter. SG Americas Securities LLC now owns 23,515 shares of the company’s stock valued at $891,000 after buying an additional 1,525 shares during the period. Icon Advisers Inc. Co. raised its stake in shares of Prestige Consumer Healthcare by 82.9% in the 3rd quarter. Icon Advisers Inc. Co. now owns 77,200 shares of the company’s stock valued at $2,925,000 after purchasing an additional 35,000 shares during the period. LSV Asset Management raised its stake in shares of Prestige Consumer Healthcare by 7.4% in the 3rd quarter. LSV Asset Management now owns 173,741 shares of the company’s stock valued at $6,583,000 after purchasing an additional 11,900 shares during the period. Rice Hall James & Associates LLC acquired a new stake in shares of Prestige Consumer Healthcare in the 3rd quarter valued at about $4,305,000. Finally, Raymond James & Associates increased its position in shares of Prestige Consumer Healthcare by 36.1% in the second quarter. Raymond James & Associates now owns 45,163 shares of the company’s stock valued at $1,733,000 after acquiring an additional 11,989 shares during the last quarter.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American Over-the-Counter (OTC) Healthcare, International OTC Healthcare, and Household Cleaning. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve.

Further Reading: Is the Dow Jones Industrial Average (DJIA) still relevant?

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply